

**Stefano Cavalieri**

📍 via Pier Paolo Pasolini 19, 20151 Milano (Italy)

📞 +39 348 0625361

✉ stefano.cavalieri@istitutotumori.mi.it

Date of birth 06/01/1988

WORK EXPERIENCE

12/2014–12/2019

**Residency in Medical Oncology**

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)

Head and Neck Medical Oncology Unit (since 11/2016) - Department of Medical Oncology

08/2013–06/2014

**Post-Graduate Internship**

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano (Italy)

Department of Oncohematology

01/2012–07/2013

**Undergraduate Internship**

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milano (Italy)

Bone Marrow Transplantation Unit - Department of Oncohematology

12/2019

**Board Certificate in Medical Oncology**

University of Milan - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)

*Thesis: A big data-based analysis of radiosensitivity through transcriptomics and radiomics in head and neck cancer patients treated with multimodality curative approaches including radiotherapy*

02/2014

**Italian Medical Licensing Examination**

University of Milan, Milano (Italy)

10/2007–07/2013

**Doctor of Medicine Degree**

University of Milan, Milano (Italy) . Graduation 19th July 2013. 110/110 cum laude

*Thesis: Autologous hematopoietic stem cell transplantation in refractory Systemic Sclerosis and Crohn's disease: a single-center experience*

07/2007

**High School Diploma**

Liceo Scientifico "Édouard Bérard", Aosta (Italy). 100/100

EDUCATION AND TRAINING

Mother tongue(s)

Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English*	C1	C1	B2	B2	C1
French	C1	C1	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user  
Common European Framework of Reference for Languages

PERSONAL SKILLS

\* IELTS overall score 7.5

## ADDITIONAL INFORMATION

### Papers

1. **Cavalieri S**, Di Guardo L, Cimminiello C, Bono A, Tolornio E, Colombetti A, Valeri B, Di Tolla G, de Braud F, Del Vecchio M. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience. *Tumori* 2016; 102(5): 501-507. [doi: 10.5301/tj.5000539]
2. Resteghini C, **Cavalieri S**, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. *Best Practice & Research Clinical Endocrinology & Metabolism* (2017). Article in press [doi: 10.1016/j.beem.2017.04.012]
3. **Cavalieri S**, Di Guardo L, Cossa M, Cimminiello C, Del Vecchio M. Unusual Skin Carcinomas Induced by BRAF inhibitor for Metastatic Melanoma: A Case Report. *Journal of Clinical and Diagnostic Research*. 2017 Jul, Vol-11(7): XD06-XD08 [doi: 10.7860/JCDR/2017/26881.10200]
4. Galli G, Bregni G, **Cavalieri S**, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paoiini B, Carcangiu ML, de Braud F, Di Cosimo S. Neoadjuvant chemotherapy exerts selection pressure towards luminal phenotype breast cancer. *Breast Care (Basel)*. 2017 Dec;12(6):391-394. [doi: 10.1159/000479582]
5. **Cavalieri S**, Morelli D, Martinetti A, Galli G, Nichetti F, de Braud F, Platania M. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. *Int J Biol Markers*. 2017 Sep 25:0. [doi: 10.5301/ijbm.5000305]
6. **Cavalieri S**, Stathis A, Fabbri A, Sonzogni A, Pelosi G, Perrone F, Tamborini E, de Braud F, Platania M. Uncommon somatic mutations in metastatic NUT midline carcinoma. *Tumori*. 2017 Nov 15;103(Suppl. 1): e5-e8. [doi: 10.5301/tj.5000685]
7. Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, De Rosa F, Picasso V, Di Guardo L, Cimminiello C, **Cavalieri S**, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P. Current status and perspectives in immunotherapy for metastatic melanoma. *Oncotarget*. 2018 Jan 3;9(15):12452-12470. [doi: 10.18632/oncotarget.23746]
8. Alfieri S, **Cavalieri S**, Licitra L. Immunotherapy for recurrent/metastatic head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg*. 2018 Apr;26(2):152-156. [doi: 10.1097/MOO.0000000000000448]
9. **Cavalieri S**, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. *Cancer Treat Rev*. 2018 Mar 20;65:78-86. [doi: 10.1016/j.ctrv.2018.03.003]
10. **Cavalieri S**, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):379-385. [doi: 10.1080/17425255.2018.1461839]
11. Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, **Cavalieri S**, Locati L, Licitra L, Paolo B. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. *Tumori*. 2018 Apr 1:300891618765558. [doi: 10.1177/0300891618765558]
12. **Cavalieri S**, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 May 4;97:7-15. [doi: 10.1016/j.ejca.2018.04.004]
13. Ripamonti CI, Antonuzzo A, Bossi P, **Cavalieri S**, Roila F, Fatigoni S. Fatigue, a major still underestimated issue. *Curr Opin Oncol*. 2018 Jul;30(4):219-225. [doi: 10.1097/CCO.0000000000000451]
14. Mariani G, Galli G, **Cavalieri S**, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: the ASTER study. *The Breast Journal*. 2019 Mar;25(2):237-242. [doi: 10.1111/tbj.13197]
15. Galli G, **Cavalieri S**, Di Guardo LA, Cimminiello C, Nichetti F, Corti F, Garcia MA, Pappalardi B, Fallai C, de Braud, Platania M, Del Vecchio M. Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis. *Oncology Research and Treatment*. 2019 Mar 5:1-6. [doi: 10.1159/000497211]
16. van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, **Cavalieri S**, Tooten S, Bos E, Quattrone P, van Herpen CML, PALGA Group. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor positive salivary duct carcinoma. *Eur J Cancer*. 2019 March; 110:62-70. [doi: 10.1016/j.ejca.2018.12.035]
17. **Cavalieri S**, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? *Expert Opin Investig Drugs*. 2019 Mar 22:1-9. [doi: 10.1080/13543784.2019.1598376]
18. **Cavalieri S**, Busico A, Capone I, Conca E, Daflera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F. Identification of potentially druggable molecular alterations in skin adnexal malignancies. *J Dermatol*. 2019 Apr 30 [doi: 10.1111/1346-8138.14889]
19. Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolè F, Codecà C, Boscolo G, Piccinini M, **Cavalieri S**, Bossi P. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. *Eur J Cancer*. 2019 May 10;115:4-12 [doi: 10.1016/j.ejca.2019.03.022]
20. **Cavalieri S**, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. *Oncology*. 2019 May 21:1-7 [doi: 10.1159/000500246]
21. Locati LD, **Cavalieri S**, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. *Head Neck*. 2019 Jul 29. [doi: 10.1002/hed.25891]
22. Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghini C, **Cavalieri S**, Bossi P, Canevari S, Licitra L, De Cecco L. Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2019 Jul 26;11(8). pii: E1057. [doi: 10.3390/cancers11081057]
23. Orlandi E, **Cavalieri S**, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, Bossi P. Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. *Laryngoscope*. 2019 Aug 1. [doi: 10.1002/lary.28202]
24. Bonomo P, Paderno A, Mattavelli D, Zenda S, **Cavalieri S**, Bossi P. Quality Assessment in Supportive Care in Head and Neck Cancer. *Front Oncol*. 2019 Sep 18;9:926. [doi: 10.3389/fonc.2019.00926]
25. Bergamini C, **Cavalieri S**, Sanguineti G, Farneti A, Licitra L. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. *Oxford Medical Case Reports*, 2019;10,436–438 [doi: 10.1093/omcr/omz102]
26. Di Cosimo S, Appierto V, Silvestri M, Pruneri G, Vingiani A, Perrone F, Busico A, Folli S, Scaperotta G, de Braud FG, Bianchi GV, **Cavalieri S**, Daidone MG, Dugo M. Targeted-Genome Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. *Cancers (Basel)*. 2019 Nov 8;11(11). pii: E1753. [doi: 10.3390/cancers11111753]

*Uffers* *Curium*

#### Curriculum vitae

##### Books

- Co-Author of the chapter "2.6 Head & Neck immuno-oncology" in the ESMO Handbook of Immuno-Oncology, ESMO Press 2018 [ISBN: 978-88-941795-7-6]
- Author of the chapter "Immunoterapia nella malattia localmente avanzata: work in progress" in "Collana di immuno-oncologia – Vol. 5 Tumori della testa e del collo". Il Pensiero Scientifico Editore, December 2017

Author or co-author of 33 abstracts accepted at National or International meetings.

##### Conference oral presentations

- Laryngeal cancer today 2019 – Consensus conference. Milan (Italy), 22/02/2019
- Grandangolo in Oncologia. Focus su terapie di supporto 2018. Bologna (Italy), 07/05/2018
- 8th ECHNO (European Congress on Head and Neck Oncology), Rome (Italy), 11/04/2018. Abstract "*Clinical prognostic factors in patients with local relapse and /or metastatic adenoid cystic carcinoma of the salivary glands*" selected as oral communication in the session "Young Scientists Forum"
- IMI (Intergruppo Melanoma Italiano - Italian Melanoma Network) Master Course, Milan (Italy), 26/11/2016
- 22nd IMI (Intergruppo Melanoma Italiano - Italian Melanoma Network) National Italian Conference, Ragusa (Italy), 15/11/2016 . Abstract "*Long-term responses in metastatic melanoma patients treated with vemurafenib*" selected as oral communication

##### Memberships

- AIOM (Italian Society of Medical Oncology) member since 2016
- ESMO (European Society for Medical Oncology) member since 2016
- ASCO (American Society of Clinical Oncology) member since 2017
- NICSO (Italian Network for Supportive Care in Oncology) member since 2018

##### Certifications

- October 2018 - ESMO Examination for Medical Oncologists
- February 2018 - University Post-graduate Course, Clinical Oncology: Head & neck cancers - University of Milan, Milano (Italy) - European School of Oncology
- September 2017 - GCP (Good Clinical Practice) Training

##### Awards

- ESMO 2018 Merit awards for the submitted abstract *Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)*, accepted as poster discussion

I hereby authorize the use of my personal data in accordance to the GDPR (General Data Protection Regulation) 679/16 - "European regulation on the protection of personal data".

23/12/2019

Lucrezio Cauter

